Immunovant

US · IMVT #1790 by market cap Listed 2017

30.83 -1.21 -3.78%

Live - 5344 symbols - heartbeat 425s ago · 2026-10-08 10:00

Pre-market 31.30 -2.31%

After-hours 32.04 0.00%

Overnight 30.98 -3.31%

Market cap: 6.37B
P/E (TTM): -10.97
P/B: 8.66
EPS: -2.77
Div yield: 0.00%
52W pos: 49%

Reader sentiment Are you bullish or bearish on IMVT?

Anonymous reader poll. Unscientific, not investment advice.

About Immunovant

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in Durham, NC.

Founded: 2018
CEO: Dr. Eric Venker, M.D.,Pharm.D.
Employees: 315
Headquarters: Durham, North Carolina, United States of America
Fiscal year end: 03-31
Website: immunovant.com

Company profile

Exchange: US
Symbol: IMVT
Market-cap rank: #1790
Listing date: 2017-05-10
Market cap: 6.37B
Float cap: 2.83B
Shares out: 206.55M
Float shares: 91.79M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 10:00:16 · For reference only, not investment advice and not tailored to your situation.